![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
Active Filter(s):
Details:
Under the license agreement, Medsenic agreed to commence a clinical study using Phebra's oral formulation OATO (arsenic trioxide) for the treatment of Graft Versus Host Disease, Systemic Sclerosis, Systemic Lupus Erythematosus and infectious diseases.
Lead Product(s): Arsenic Trioxide
Therapeutic Area: Immunology Product Name: OATO
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: Phebra
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement May 29, 2023
Details:
The acquisition of Medsenic and its specialized pipeline in the development of optimized formulations of arsenic trioxide (Arscimed) and their applications in serious inflammatory/autoimmune conditions and other potential new indications.
Lead Product(s): Arsenic Trioxide
Therapeutic Area: Immunology Product Name: Arscimed
Highest Development Status: Phase III Product Type: Small molecule
Recipient: Bone Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition October 25, 2022
Details:
Bone Therapeutics would also issue and automatically allot one subscription right to each outstanding share of Bone Therapeutics, in case of statistically positive interim results of the ALLOB Phase IIb trial.
Lead Product(s): Allogeneic Bone Cell Therapy
Therapeutic Area: Orthopedics/Orthopedic Surgery Product Name: ALLOB
Highest Development Status: Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Bone Therapeutics
Deal Size: $5.0 million Upfront Cash: $5.0 million
Deal Type: Acquisition August 10, 2022
Details:
First-line combination of Arscimed (arsenic trioxide) and prednisone in cGvHD showed an Overall Response Rate (ORR) at 6 months of 75%, allowing rapid corticosteroid tapering.
Lead Product(s): Arsenic Trioxide
Therapeutic Area: Immunology Product Name: Arscimed
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 18, 2022
Details:
The primary endpoint of this prospective, multicenter, non-randomized study was the improvement of treatment response with Arscimed® (arsenic trioxide) in combination with prednisone, with or without cyclosporine.
Lead Product(s): Arsenic Trioxide,Prednisone,Cyclosporine
Therapeutic Area: Immunology Product Name: Arscimed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 20, 2022
Details:
Arsenic trioxide has the unique property of increasing cellular oxidative stress to the point where it induces cell death of activated cells (enhanced apoptosis). It also has an effect on pro-inflammatory cytokines.
Lead Product(s): Arsenic Trioxide
Therapeutic Area: Immunology Product Name: Arscimed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 29, 2021
Details:
Exclusive licensing agreement for the development of a patented formulation of oral arsenic trioxide in the treatment of autoimmune diseases. Initially the oral formulation of arsenic trioxide will target the treatment of patients with chronic graft-versus-host disease.
Lead Product(s): Arsenic Trioxide
Therapeutic Area: Immunology Product Name: Arscimed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Phebra
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership June 30, 2021